Payers, providers, and patients are demanding more than the FDA standards of safety and efficacy to justify the value of drugs and devices. They want to know the value of treatments for specific subsets of patients in order to support formulary and purchasing decisions, clinical guideline development, and decision support at the point of care. EHR-based real-world evidence (RWE) is widely purported as a promising tool for delivering on those demands.

At Advisory Board’s 2019 Cross-Industry Value Summit, we convened a cohort of leaders from payer, provider, life sciences, and evaluator organizations to better understand the challenges and opportunities around EHR-based RWE. Attendees discussed how to leverage data stored in EHRs to measure value, and how to overcome barriers preventing them from doing so today.

This briefing outlines key takeaways that emerged from Advisory Board’s research and the live Summit discussion.